Cancer clinical trials in the region Île-de-France
750 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT06641414
#2024-517247-31-00
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required IPSS-R prognostic scores
High
Very high
Required IPSS-M prognostic scores
High
Very high
Excluded previous treatments
Allogeneic stem cell transplant
13 recruiting sites
Ascentage Pharma Group Inc.
Phase 3
Liver and bile duct cancer
#NCT06467357
#2023-508057-19-00
Required histologic sub types
Intrahepatic cholangiocarcinoma
Extrahepatic cholangiocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Targeted therapy
Antibody Drug Conjugates (ADC)
8 recruiting sites
AstraZeneca
Phase 3
Endometrial cancer
#NCT05255653
#2023-503267-42-00
Required histologic sub types
Endometrioid adenocarcinoma
Serous adenocarcinoma
Clear cell carcinoma
Dedifferentiated and undifferentiated endometrial ...
Carcinosarcoma
Other
Required FIGO stages
Stage I
Stage II
Stage III
Required disease stage
Localized
Locally Advanced
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Surgery
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Surgery
Excluded genetic anomalies
POLE
Excluded previous treatments at localized stage
Immunotherapy
Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Radiotherapy
10 recruiting sites
Centre médical universitaire de Leiden
Phase 3
Sarcoma and GIST
#NCT06127407
#2023-508507-20-00
Required histologic types
Bone sarcoma
Required histologic sub types
Chondrosarcoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Chemotherapy
Targeted therapy
9 recruiting sites
Phase 3
Prostate cancer
#NCT05974774
#2023-506817-23-01
Required disease stage
Metastatic Hormone-sensitive
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Hormone therapy
9 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3
Stomach and esophageal cancer
#NCT06901531
Required histologic types
Stomach
Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5)
CPS Positive (5 <= X < 10)
CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
17 recruiting sites
Astellas Pharma Développement mondial, Inc.
Phase 3
Bladder / Urinary Tract / Urethral cancer
#NCT06960577
#2024-519246-75-01
Required histologic types
Invasive bladder cancer
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy
Chemotherapy
17 recruiting sites
AstraZeneca
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT06499285
#2024-516009-22-00
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Required number of previous lines of therapy
1
Required previous treatments
EPO / Growth factors
Required medullary blasts
< 5 %
Required transfusion dependency statuses
Transfusion-dependent
Required IPSS-R prognostic scores
Very low
Low
Intermediate
Excluded genetic anomalies
del(5q)
Excluded previous treatments
Systemic Treatment-Naive
Chemotherapy
Allogeneic stem cell transplant
Erythroid maturation agent
4 recruiting sites
Takeda
Phase 3
Colon cancer
Rectal cancer
#NCT07549412
#2025-524648-37-00
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
EMD Serono Research & Development Institute, Inc.
Phase 3
Lung cancer
#NCT07431827
#2024-517337-41-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Localized
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Surgery
Immunotherapy
Chemotherapy
2 recruiting sites
Merck Sharp & Dohme LLC